Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities

Progress in Retinal and Eye Research(2020)10.1016/j.preteyeres.2020.100906Source: DataRank Database

Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities is a research paper published in Progress in Retinal and Eye Research (2020). On theSindex it has a DataRank of 0. It has been cited 375 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access375 citations

Download PDF

Cite:

Linked data & code

refsnp nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 21.80)OA: greenTopics (42)Linked Datasets (22)DataCite Reuse (22)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Michael J. Allingham,Scott W. Cousins ORCID,Priyatham S. Mettu

Live enrichment

PubMed:33022379 PMC:PMC10368393 OpenAlex:https://openalex.org/W3089551374

NEI NIH HHS

Grant: R03 EY015292

NEI NIH HHS

Grant: R01 EY013318

NEI NIH HHS

Grant: R01 EY018880

NEI NIH HHS

Grant: K08 EY026627

NEI NIH HHS

Grant: P30 EY005722

NEI NIH HHS

Grant: K08 EY025325

National Institutes of Health

Research to Prevent Blindness

Bausch and Lomb

FWCI

21.80

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10368393/pdf/nihms-1641342.pdf

publisherhttps://api.elsevier.com/content/article/PII:S1350946220300781?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1350946220300781?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10368393

Fields of Study

Retinal Diseases and TreatmentsRetinal Imaging and AnalysisRetinal Development and DisordersAngiogenesis InhibitorsAnimalsChoroidal NeovascularizationHumansIntravitreal InjectionsMiceVascular Endothelial Growth Factor AVisual AcuityWet Macular Degeneration

MeSH Terms

AnimalsHumansVisual AcuityChoroidal NeovascularizationAngiogenesis InhibitorsVascular Endothelial Growth Factor AMiceWet Macular DegenerationIntravitreal Injections

Keywords

Macular degenerationMedicineLesionChoroidal neovascularizationMyofibroblastFibrosisPathologyBioinformaticsOphthalmologyBiologyMacrophageMonocyteNeovascular Age-related Macular DegenerationAnti-vegfMüller CellMesenchymal Precursor CellNeovascular RemodelingAnti-vegf ResistancePersistent Disease ActivitySuboptimal Vision RecoveryPhotoreceptor Synaptic Dysfunction

Additional file 1 of A short peptide derived from pigment epithelial-derived factor exhibits an angioinhibitory effect

10.6084/m9.figshare.19218591.v1figshare

Additional file 1 of A short peptide derived from pigment epithelial-derived factor exhibits an angioinhibitory effect

10.6084/m9.figshare.19218591figshare

Additional file 1 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.24550038.v1figshare

Additional file 1 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.24550038figshare

Additional file 2 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.24550309.v1figshare

Additional file 2 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.24550309figshare

Additional file 1 of Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration

10.6084/m9.figshare.25485812.v1figshare

Additional file 1 of Wnt5a/β-catenin-mediated epithelial-mesenchymal transition: a key driver of subretinal fibrosis in neovascular age-related macular degeneration

10.6084/m9.figshare.25485812figshare

Additional file 3 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.26638650.v1figshare

Additional file 3 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.26638650figshare

Additional file 4 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.26638653.v1figshare

Additional file 4 of Retinal layers changes in patients with age-related macular degeneration treated with intravitreal anti-VEGF agents

10.6084/m9.figshare.26638653figshare

Additional file 5 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715433.v1figshare

Additional file 5 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715433figshare

Additional file 1 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715421figshare

Additional file 4 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715430.v1figshare

Additional file 2 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715424.v1figshare

Additional file 2 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715424figshare

Additional file 4 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715430figshare

Additional file 1 of Deciphering Müller cell heterogeneity signatures in diabetic retinopathy across species: an integrative single-cell analysis

10.6084/m9.figshare.26715421.v1figshare

Related Papers (6)

Single-cell chromatin state analysis with Signac

N/A

1.1DataRank · unranked

Nature Methods(2021)

co-cited

10.1038/s41592-021-01282-5

VEGF Mediates Retinal Müller Cell Viability and Neuroprotection through BDNF in Diabetes

Biomolecules(2021)

co-cited

10.3390/biom11050712

Excitatory neurotransmission activates compartmentalized calcium transients in Müller glia without affecting lateral process motility

N/A

0.591DataRank · unranked

eLife(2021)

co-cited

10.7554/elife.73202

Cross-species scRNA-seq reveals the cellular landscape of retina and early alterations in type 2 diabetes mice

N/A

0.477DataRank · unranked

Genomics(2023)

co-cited

10.1016/j.ygeno.2023.110644

limma powers differential expression analyses for RNA-sequencing and microarray studies

N/A

1.6DataRank · unranked

Nucleic Acids Research(2015)

co-cited

10.1093/nar/gkv007

Intercellular contact and cargo transfer between Müller glia and to microglia precede apoptotic cell clearance in the developing retina

Development(2024)

co-cited

10.1242/dev.202407

Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities

FAIR Checklist

Authors (3)

Funding (9 grants)

Impact

Open Access

Topics

Linked Datasets (22)

Annotations (Europe PMC)

Related Papers (6)